covid
Buscar en
Revista Colombiana de Anestesiología
Toda la web
Inicio Revista Colombiana de Anestesiología Sistemas de soporte hepático extracorpóreo
Journal Information
Vol. 39. Issue 4.
Pages 528-543 (November - January 2012)
Share
Share
Download PDF
More article options
Vol. 39. Issue 4.
Pages 528-543 (November - January 2012)
ARTÍCULO DE REVISIÓN
Open Access
Sistemas de soporte hepático extracorpóreo
Extracorporeal Liver Support Systems
Visits
3215
Fredy Ariza Cadena
,
Corresponding author
fredyariza@hotmail.com

Correspondencia: Carrera 98 No. 18–49 Cali, Colombia.
, Luis Felipe Carmona Serna**, Iván Fernando Quintero C.***, Luis Armando Caicedo*, Carlos A. Vidal Perdomo*, Luis Fernando González*
* Departamento de Trasplante de Órganos Sólidos, Fundación Valle del Lili, Cali, Colombia.
** Anestesiólogo, Hospital de la Misericordia. Bogotá, Colombia.
*** Residente de Anestesiología. Universidad del Valle. Cali, Colombia.
This item has received

Under a Creative Commons license
Article information
RESUMEN
Introducción.

Los sistemas de soporte hepático extracorpóreo (SHE) surgen como una alternativa al trasplante hepático (TH), dado el incremento en la incidencia de falla hepática aguda (FHA), falla hepática crónica agudizada (FHCA), así como las restricciones en la oferta de órganos.

Objetivo.

Revisión de la literatura de los sistemas de soporte hepático extracorporeo.

Metodología.

Búsqueda de la literatura publicada entre julio de 1990 y noviembre de 2010 en las principales bases de datos médicas que incluyeron MEDLINE, SciELO y EMBASE, de artículos que analizaran tecnologías relacionadas con sistemas de soporte hepático en cuanto a sus especificaciones técnicas, sus usos y la evidencia respecto a su efectividad en pacientes con algún tipo de falla hepática que requirieran soporte.

Resultados.

Estos sistemas pueden dividirse en artificiales (hemofiltración, sistema MARS) y bioartificiales (como el Hepatassist™). Su fundamento consiste en reemplazar los procesos de destoxificación relacionados específicamente con el sistema de bilirrubinas, la eliminación de aminoácidos aromáticos, agentes inflamatorios y el manejo de los productos de degradación del sistema de la coagulación. Los recientes avances en bioingeniería y biogenética han hecho que estas tecnologías se acerquen cada vez más a una forma ideal, permitiendo que sean utilizados con relativo éxito en humanos. Los SHE, en su gran mayoría en desarrollo, pretenden no solo actuar como puente al TH, sino que, en casos puntuales, pueden llegar a ser la piedra angular del tratamiento mientras la FHA logra resolverse.

Palabras clave::
Insuficiencia hepática
fallo hepático agudo
hígado artificial
fallo hepático. (Fuente: DeCS, BIREME).
SUMMARY
Background.

Extracorporeal liver support systems (ELS) have emerged as an alternative to liver transplant (LT), given the growing incidence of acute liver failure (ALF), acute-on-chronic liver failure (ACLF) and the limited organ supply.

Objective.

Review of literature about Extracorporeal Liver Support Systems.

Methodology.

A literature search was conducted on the main medical databases including MEDLINE, SciELO and EMBASE for papers published between July 1990 and November 2010 looking at technologies associated with liver support systems, their technical specifications, their use, and evidence regarding their effectiveness in patients with some forms of liver failure requiring support.

Results.

These systems may be divided into artificial (hemofiltration, MARS) and bioartificial (such as the Hepatassist™). They work by replacing detoxification processes associated specifically with bilirubins, aromatic aminoacids, and inflammatory agents, and the elimination of breakdown products of coagulation. Recent advances in bioengineering and biogenetics have brought these technologies closer to the ideal, enabling their use in humans with a relative degree of success. ELS systems, most of them still under development, are designed not only to act as a bridge for LT but may also become the cornerstone of treatment in specific cases while the ALF resolves.

Keywords:
Hepatic insufficiency
liver
artificial
liver failure
liver failure
acute. (Source: MeSH, NLM).
Full text is only aviable in PDF
REFERENCES
[1.]
W.A. Bower, M. Johns, H.S. Margolis, I.T. Williams, B.P. Bell.
Population-based surveillance for acute liver failure.
Am J Gastroenterol, 102 (2007 Nov), pp. 2459-2463
[2.]
A. Escorsell, A. Mas, M. De la Mata.
Acute liver failure in Spain: analysis of 267 cases.
Liver Transpl, 13 (2007 Oct), pp. 1389-1395
[3.]
W. Bernal, G. Auzinger, A. Dhawan, J. Wendon.
Acute liver failure.
Lancet, 376 (2010 Jul 17), pp. 190-201
[4.]
F. Sierra.
Acute liver failure: Socratic and hypothetic discussion with the resident.
Rev Col Gastroenterol, 21 (2006 Sep), pp. 182-189
[5.]
W. Bernal, T.J. Cross, G. Auzinger, E. Sizer, M.A. Heneghan, M. Bowles.
Outcome after wait-listing for emergency liver transplantation in acute liver failure: a single centre experience.
J Hepatol, 50 (2009 Feb), pp. 306-313
[6.]
A. Mas, A. Escorsell, J. Fernandez.
Liver transplantation for acute liver failure: a spanish perspective.
Transplant Proc, 42 (2010 Mar), pp. 619-621
[7.]
G. Atienza Merino.
Evaluation of extracorporeal liver support systems in the treatment of liver failure. A systematic review.
Gastroenterol Hepatol, 33 (2010 May), pp. 352-362
[8.]
B. Carpentier, A. Gautier, C. Legallais.
Artificial and bioartificial liver devices: present and future.
Gut, 58 (2009 Dec), pp. 1690-1702
[9.]
S. Lafuente, M.J. Bertran, A. Escorsell.
Artificial liver support. Literature review.
Med Clin (Barc), (2010 Apr 21),
[10.]
T.J. McKenzie, J.B. Lillegard, S.L. Nyberg.
Artificial and bioartificial liver support.
Semin Liver Dis, 28 (2008 May), pp. 210-217
[11.]
J. Phua, K.H. Lee.
Liver support devices.
Curr Opin Crit Care, 14 (2008 Apr), pp. 208-215
[12.]
A. Santoro, E. Mancini, E. Ferramosca, S. Faenza.
Liver support systems.
Contrib Nephrol, 156 (2007), pp. 396-404
[13.]
V. Stadlbauer, R. Jalan.
Acute liver failure: liver support therapies.
Curr Opin Crit Care, 13 (2007 Apr), pp. 215-221
[14.]
J.T. DiPiro, R.L. Talbert, G.C. Yee, G.R. Matzke, B.G. Wells, L.M. Posey.
Pharmacoterapy: a pathophysiologic approach.
7 ed,
[15.]
J.O. Clemmesen, F.S. Larsen, J. Kondrup, B.A. Hansen, P. Ott.
Cerebral herniation in patients with acute liver failure is correlated with arterial ammonia concentration.
Hepatology, 29 (1999 Mar), pp. 648-653
[16.]
J.P. Liu, L.L. Gluud, B. Als-Nielsen, C. Gluud.
Artificial and bioartificial support systems for liver failure.
Cochrane Database Syst Rev, (2004),
[17.]
N. Kobayashi.
Life support of artificial liver: development of a bioartificial liver to treat liver failure.
J Hepatobiliary Pancreat Surg, 16 (2009), pp. 113-117
[18.]
A. Davenport, E.J. Will, A.M. Davison.
Effect of renal replacement therapy on patients with combined acute renal and fulminant hepatic failure.
Kidney Int Suppl, 41 (1993 Jun), pp. S245-S251
[19.]
M.V. Catalina-Rodríguez, R. Banares-Canizares.
Artificial liver support systems: update on albumin dialysis (MARS).
Gastroenterol Hepatol, 28 (2005 Oct), pp. 453-460
[20.]
M. Boyle, J. Kurtovic, D. Bihari, S. Riordan, C. Steiner.
Equipment review: the molecular adsorbents recirculating system (MARS).
Crit Care, 8 (2004 Aug), pp. 280-286
[21.]
H. Isoniemi, A.M. Koivusalo, H. Repo, I. Ilonen, K. Hockerstedt.
The effect of albumin dialysis on cytokine levels in acute liver failure and need for liver transplantation.
Transplant Proc, 37 (2005 Mar), pp. 1088-1090
[22.]
A. Chiu, S.T. Fan.
MARS in the treatment of liver failure: controversies and evidence.
Int J Artif Organs, 29 (2006 Jul), pp. 660-667
[23.]
L.M. Guo, J.Y. Liu, D.Z. Xu, B.S. Li, H. Han, L.H. Wang.
Application of Molecular Adsorbents Recirculating System to remove NO and cytokines in severe liver failure patients with multiple organ dysfunction syndrome.
Liver Int, 23 (2003), pp. 16-20
[24.]
V. Stadlbauer, G.A. Wright, R. Jalan.
Role of artificial liver support in hepatic encephalopathy.
Metab Brain Dis, 24 (2009 Mar), pp. 15-26
[25.]
I. Ilonen, A.M. Koivusalo, K. Hockerstedt, H. Isoniemi.
Albumin dialysis has no clear effect on cytokine levels in patients with life-threatening liver insufficiency.
Transplant Proc, 38 (2006 Dec), pp. 3540-3543
[26.]
R. Gaspari, A.W. Avolio, L. Zileri Dal Verme, S. Agnes, R. Proietti, M. Castagneto.
Molecular adsorbent recirculating system in liver transplantation: safety and efficacy.
Transplant Proc, 38 (2006 Dec), pp. 3544-3551
[27.]
T. Kantola, A.M. Koivusalo, K. Hockerstedt, H. Isoniemi.
The effect of molecular adsorbent recirculating system treatment on survival, native liver recovery, and need for liver transplantation in acute liver failure patients.
Transpl Int, 21 (2008 Sep), pp. 857-866
[28.]
H.K. Tan.
Molecular adsorbent recirculating system (MARS).
Ann Acad Med Singapore, 33 (2004 May), pp. 329-335
[29.]
G.D. Wagholikar, K.H. Lee, D. Pandey, S.O. Leong, R. Singh, K.C. Tan.
Pre-transplant optimization by molecular adsorbent recirculating system in patients with severely decompensated chronic liver disease.
Indian J Gastroenterol, 26 (2007 May-Jun), pp. 110-112
[30.]
W. Laleman, A. Wilmer, P. Evenepoel, I.V. Elst, M. Zeegers, Z. Zaman.
Effect of the molecular adsorbent recirculating system and Prometheus devices on systemic haemodynamics and vasoactive agents in patients with acute-on-chronic alcoholic liver failure.
Crit Care, 10 (2006), pp. R108
[31.]
W.K. Lai, G. Haydon, D. Mutimer, N. Murphy.
The effect of molecular adsorbent recirculating system on pathophysiological parameters in patients with acute liver failure.
Intensive Care Med, 31 (2005 Nov), pp. 1544-1549
[32.]
G. Donati, F. Piscaglia, L. Coli, E. Silvagni, R. Righini, P. Pini.
Acute systemic, splanchnic and renal haemodynamic changes induced by molecular adsorbent recirculating system (MARS) treatment in patients with end-stage cirrhosis.
Aliment Pharmacol Ther, 26 (2007 Sep 1), pp. 717-726
[33.]
K.H. Lee, M.K. Lee, D.S. Sutedja, S.G. Lim.
Outcome from molecular adsorbent recycling system (MARS) liver dialysis following drug-induced liver failure.
Liver Int, 25 (2005 Oct), pp. 973-977
[34.]
J.L. Montero, J.C. Pozo, P. Barrera, E. Fraga, G. Costan, J.L. Dominguez.
Treatment of refractory cholestatic pruritus with molecular adsorbent recirculating system (MARS).
Transplant Proc, 38 (2006 Oct), pp. 2511-2513
[35.]
L.E. Schmidt, L.B. Svendsen, V.R. Sorensen, B.A. Hansen, F.S. Larsen.
Cerebral blood flow velocity increases during a single treatment with the molecular adsorbents recirculating system in patients with acute on chronic liver failure.
Liver Transpl, 7 (2001 Aug), pp. 709-712
[36.]
V. Stadlbauer, N.A. Davies, S. Sen, R. Jalan.
Artificial liver support systems in the management of complications of cirrhosis.
Semin Liver Dis, 28 (2008 Feb), pp. 96-109
[37.]
C. Camus, S. Lavoue, A. Gacouin, Y. Le Tulzo, R. Lorho, K. Boudjema.
Molecular adsorbent recirculating system dialysis in patients with acute liver failure who are assessed for liver transplantation.
Intensive Care Med, 32 (2006 Nov), pp. 1817-1825
[38.]
A. Chiu, L.M. Chan, S.T. Fan.
Molecular adsorbent recirculating system treatment for patients with liver failure: the Hong Kong experience.
Liver Int, 26 (2006 Aug), pp. 695-702
[39.]
E.B. Bachli, R.A. Schuepbach, M. Maggiorini, R. Stocker, B. Mullhaupt, E.L. Renner.
Artificial liver support with the molecular adsorbent recirculating system: activation of coagulation and bleeding complications.
Liver Int, 27 (2007 May), pp. 475-484
[40.]
C. Doria, L. Mandala, J.D. Smith, G. Caruana, V.L. Scott, S. Gruttadauria.
Thromboelastography used to assess coagulation during treatment with molecular adsorbent recirculating system.
Clin Transplant, 18 (2004 Aug), pp. 365-371
[41.]
H.K. Tan, W.S. Yang, P. Chow, H.F. Lui, H.L. Choong, K.S. Wong.
Anticoagulation minimization is safe and effective in albumin liver dialysis using the molecular adsorbent recirculating system.
Artif Organs, 31 (2007 Mar), pp. 193-199
[42.]
P. Faybik, A. Bacher, S.A. Kozek-Langenecker, H. Steltzer, C.G. Krenn, S. Unger.
Molecular adsorbent recirculating system and hemostasis in patients at high risk of bleeding: an observational study.
Crit Care, 10 (2006 Feb), pp. R24
[43.]
F.P. Hessel.
Economic evaluation of the artificial liver support system MARS in patients with acute-on-chronic liver failure.
Cost Eff Resour Alloc, 4 (2006), pp. 16
[44.]
F.P. Hessel, P. Bramlage, J. Wasem, S.R. Mitzner.
Cost-effectiveness of the artificial liver support system MARS in patients with acute-on-chronic liver failure.
Eur J Gastroenterol Hepatol, 22 (2010 Feb), pp. 213-220
[45.]
B. Wolff, K. Machill, D. Schumacher, I. Schulzki.
MARS dialysis in decompensated alcoholic liver disease: a single-center experience.
Liver Transpl, 13 (2007 Aug), pp. 1189-1192
[46.]
C.T. Wai, S.G. Lim, M.O. Aung, Y.M. Lee, D.S. Sutedja, Y.Y. Dan.
MARS: a futile tool in centres without active liver transplant support.
Liver Int, 27 (2007 Feb), pp. 69-75
[47.]
M. Oppert, S. Rademacher, K. Petrasch, A. Jorres.
Extracorporeal liver support therapy with Prometheus in patients with liver failure in the intensive care unit.
Ther Apher Dial, 13 (2009 Oct), pp. 426-430
[48.]
A. Saito.
Current progress in blood purification methods used in critical care medicine.
Contrib Nephrol, 166 (2010), pp. 100-111
[49.]
K. Rifai, T. Ernst, U. Kretschmer, H. Haller, M.P. Manns, D. Fliser.
Removal selectivity of Prometheus: a new extracorporeal liver support device.
World J Gastroenterol, 12 (2006 Feb 14), pp. 940-944
[50.]
P. Evenepoel, W. Laleman, A. Wilmer, K. Claes, D. Kuypers, B. Bammens.
Prometheus versus molecular adsorbents recirculating system: comparison of efficiency in two different liver detoxification devices.
Artif Organs, 30 (2006 Apr), pp. 276-284
[51.]
V. Stadlbauer, P. Krisper, R. Aigner, B. Haditsch, A. Jung, C. Lackner.
Effect of extracorporeal liver support by MARS and Prometheus on serum cytokines in acute-on-chronic liver failure.
Crit Care, 10 (2006), pp. R169
[52.]
J. Meyburg, G.F. Hoffmann.
Liver, liver cell and stem cell transplantation for the treatment of urea cycle defects.
Mol Genet Metab, 100 (2010), pp. S77-S83
[53.]
L.L. Kjaergard, J. Liu, B. Als-Nielsen, C. Gluud.
Artificial and bioartificial support systems for acute and acute-on-chronic liver failure: a systematic review.
JAMA, 289 (2003 Jan 8), pp. 217-222
[54.]
K. Onodera, H. Sakata, M. Yonekawa, A. Kawamura.
Artificial liver support at present and in the future.
J Artif Organs, 9 (2006), pp. 17-28
[55.]
E. Varo Pérez, J.F. Castroagudin.
The future of liver transplantation.
Transplant Proc, 42 (2010 Mar), pp. 613-616
Copyright © 2011. Revista Colombiana de Anestesiología
Download PDF
Article options